1. Academic Validation
  2. AZD7545 is a selective inhibitor of pyruvate dehydrogenase kinase 2

AZD7545 is a selective inhibitor of pyruvate dehydrogenase kinase 2

  • Biochem Soc Trans. 2003 Dec;31(Pt 6):1168-70. doi: 10.1042/bst0311168.
J A Morrell 1 J Orme R J Butlin T E Roche R M Mayers E Kilgour
Affiliations

Affiliation

  • 1 AstraZeneca, Alderley Park, Macclesfield, Cheshire, SK10 4TG, U.K.
Abstract

The PDH (pyruvate dehydrogenase) multi-enzyme complex catalyses a key regulatory step in oxidative glycolysis. Phosphorylation of the E1 subunit of the complex on serine residues results in the inactivation of Enzyme activity. A family of four dedicated PDH kinase isoenzymes exists, each of which displays a distinct tissue-specific expression profile. AZD7545 is one of a series of PDH kinase inhibitors developed for the treatment of type 2 diabetes. The isoenzyme-selectivity profile of AZD7545 and related compounds is described and the consequences for their in vivo mode of action are discussed.

Figures
Products